Abstract
Background Randomised trials provide high-quality data on the effects of antibiotics for urinary tract infections (UTI) but are prone to selection bias and may not accurately reflect effects in those who actually consume antibiotics.
Aim To estimate the effect of antibiotic consumption, rather than prescription, on self-reported time to recovery in women with uncomplicated UTI.
Design and setting Secondary analysis of data from a randomised control trial on point of care diagnostic to guide antibiotic prescribing in primary care. Antibiotic prescribing decisions were not mandated by the trial protocol.
Methods 413 adult women presenting with UTI symptoms and who either consumed (n=333) or did not consume (n=80) one or more doses of antibiotics during a 14-day follow-up were included. Antibiotic consumption was standardised using defined daily dose (DDD) and described as “days-worth of antibiotics”. Cox-proportional hazard model was used to estimate the effect of antibiotic consumption upon time to self-reported recovery, controlling for potential confounders and propensity of consuming antibiotics based on baseline symptom severity and history of UTI treatment.
Results The crude median time to recovery was 3 days longer among patients who did not consume antibiotics (10 days; 95% CI= 8.5-11.5) compared to those who consumed antibiotics (7 days; 95% CI= 6.5-7.5). Patients who consumed >0 to <3, ≥3 to ≤5, and >5 days-worth of antibiotics recovered at approximately 2 – 3 times faster than the rate of those who consumed no antibiotics, adjusted HR 3.2 (95% CI 2.0, 5.1), 2.8 (1.8, 4.3), 2.3 (1.5, 3.7), respectively.
Conclusion Consuming antibiotics was associated with a reduction in self-reported time to recovery in this study which is consistent with results from previous trials.
Competing Interest Statement
The authors have declared no competing interest, except Dr. Francis reports grants from European Union FP7, during the conduct of the study; personal fees and non-financial support from Abbott, outside the submitted work. Dr. Llor reports grants from Abbott Diagnostics, outside the submitted work.
Funding Statement
This secondary analysis was supported by Cardiff University Intercalated BSc in Population Medicine Program 2018/2019
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
POETIC was approved in the UK by the Research Ethics Committee for Wales (now known as Wales REC3) (reference: 12/WA/0394). Jordi Gol i Gurina Ethics Committee in Barcelona (reference: AC13/01) and the Medical Research Ethics Committee of UMC Utrecht (reference: 13/304) in the Netherlands. The use of data for future studies concerning UTI diagnosis and management was consented for during the POETIC study. All patients data were completely anonymised for the current study research team.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymised data will be available upon request. The corresponding author or the senior authors (Nick Francis: nick.francis{at}soton.ac.uk and Chris Butler: christopher.butler{at}phc.ox.ac.uk) can receive email requests.
